1
|
Padial-Molina M, Gonzalez-Perez G, Martin-Morales N, Sanchez-Fernandez E, O'Valle F, Galindo-Moreno P. Periostin in the relation between periodontal disease and atherosclerotic coronary artery disease: A pilot randomized clinical study. J Periodontal Res 2024; 59:446-457. [PMID: 38140743 DOI: 10.1111/jre.13229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/30/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023]
Abstract
OBJECTIVE The aim of this study was to analyze the effects of periodontal treatment on markers of atherosclerotic coronary artery disease and circulating levels of periostin. BACKGROUND Periostin is necessary for periodontal stability, but it is highly present in atherosclerotic plaques. Treatment of periodontal disease, with low levels of local periostin, is thought to reduce systemic levels of periostin. Thus, this may contribute to cardiovascular health. METHODS A pilot randomized controlled clinical trial was designed to include patients with severe periodontal disease and history of atherosclerotic coronary artery disease. Samples of gingival crevicular fluid (GCF) and serum were collected before and after periodontal treatment by periodontal surgery or non-surgical therapy. The levels of several markers of inflammation and cardiovascular damage were evaluated including CRP, IFN-γ, IL-1ß, IL-10, MIP-1α, periostin, and TNF-α in GCF and CRP, Fibrinogen, IFN-γ, IL-1ß, IL-6, IL-10, L-Selectin, MIP-1α, Periostin, TNF-α, and vWF in serum. RESULTS A total of 22 patients with an average of 56 years old were recruited for participating in this study. Twenty of them were male. Most of them (82%) had suffered an acute myocardial event and underwent surgery for placing 1, 2, or 3 stents in the coronary arteries more than 6 months ago but less than 1 year. The treatment of periodontal disease resulted in an overall improvement of all periodontal parameters. Regarding the evaluation of GCF and serum, a significant increase of periostin in the GCF was observed after periodontal surgery. In contrast, although other markers in GCF and serum improved, no significant correlations were found. CONCLUSION Treatment of periodontal disease through periodontal surgery induces a local and transient increase in the levels of periostin in the gingival crevicular fluid. The effects on systemic markers of inflammation and cardiovascular function have not been confirmed.
Collapse
Affiliation(s)
- Miguel Padial-Molina
- Department of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
| | - Gloria Gonzalez-Perez
- PhD Program in Clinical Medicine and Public Health, University of Granada, Granada, Spain
| | - Natividad Martin-Morales
- Department of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
- PhD Program in Biomedicine, University of Granada, Granada, Spain
- Department of Pathology, School of Medicine, University of Granada, Granada, Spain
| | - Elena Sanchez-Fernandez
- Department of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
| | - Francisco O'Valle
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
- Department of Pathology, School of Medicine, University of Granada, Granada, Spain
- Institute of Biopathology and Regenerative Medicine (IBIMER, CIBM), University of Granada, Granada, Spain
| | - Pablo Galindo-Moreno
- Department of Oral Surgery and Implant Dentistry, School of Dentistry, University of Granada, Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
| |
Collapse
|
2
|
Yuan C, Li J. Research progress of periostin and osteoporosis. Front Endocrinol (Lausanne) 2024; 15:1356297. [PMID: 38487345 PMCID: PMC10938139 DOI: 10.3389/fendo.2024.1356297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Accepted: 02/05/2024] [Indexed: 03/17/2024] Open
Abstract
Periostin, as a unique extracellular matrix, is mainly produced during ontogeny and in adult connective tissues that bear mechanical loads, such as heart valves, skin, periodontal ligaments, tendons, and bones. By binding to the integrin on the cell surface and activating Wnt/β-catenin, NF-κB, Fak and other signaling pathways, it regulates the tissues in vivo positively or negatively, and also has different effects on the occurrence and development of various diseases. Periostin is an important factor, which can promote cell proliferation, stimulate tissue repair and maintain the integrity of the structure and function of connective tissue. It also promotes the formation, regeneration and repairation of bone. Recent studies have shown that periostin is important in bone metabolic diseases. The increased expression of periostin can affect bone mineral density at different sites, and its relationship with traditional biochemical markers of bone turnover has not been conclusively established. This article reviews the research results and potential applications of periostin in osteoporosis.
Collapse
Affiliation(s)
| | - Junyan Li
- Department of Endocrinology and Metabolism, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, China
| |
Collapse
|
3
|
Pickering ME, Oris C, Chapurlat R. Periostin in Osteoporosis and Cardiovascular Disease. J Endocr Soc 2023; 7:bvad081. [PMID: 37362382 PMCID: PMC10285762 DOI: 10.1210/jendso/bvad081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Indexed: 06/28/2023] Open
Abstract
Context Osteoporosis (OP) and cardiovascular disease (CVD), prevalent disorders worldwide, often coexist and share common risk factors. The identification of common biomarkers could significantly improve patients' preventive care. Objectives The objectives are 1, to review periostin (Postn) involvement in osteoporosis and in CVD, and 2, identify if Postn could be a common biomarker. Design This is a scoping review on Postn in OP and CVD. Methods Databases were searched, in vitro and in vivo, for publications in English on Postn, bone, and the cardiovascular system, with no limit regarding publication date. Results Postn appears as a key factor in OP and CVD. Its role as a potential biomarker in both pathologies is described in recent studies, but a number of limitations have been identified. Conclusions Current evidence provides fragmented views on Postn in OP and CVD and does not encapsulate Postn as a common pivotal thread linking these comorbidities. A number of gaps impede highlighting Postn as a common biomarker. There is room for future basic and clinical research with Postn as a marker and a target to provide new therapeutic options for aging patients with concomitant OP and CVD.
Collapse
Affiliation(s)
- Marie-Eva Pickering
- Correspondence: Marie-Eva Pickering, MD, Rheumatology Department, CHU Gabriel Montpied, 58 rue Montalembert, 63000 Clermont-Ferrand, France.
| | - Charlotte Oris
- Service de Biologie, CHU Gabriel Montpied, 63000 Clermont-Ferrand, France
| | - Roland Chapurlat
- Service de Rhumatologie, Hospices Civils de Lyon, 69437 Lyon, Cedex 03, France
- Inserm UMR 1033, 69437 Lyon, Cedex 03, France
| |
Collapse
|
4
|
Manta CP, Leibing T, Friedrich M, Nolte H, Adrian M, Schledzewski K, Krzistetzko J, Kirkamm C, David Schmid C, Xi Y, Stojanovic A, Tonack S, de la Torre C, Hammad S, Offermanns S, Krüger M, Cerwenka A, Platten M, Goerdt S, Géraud C. Targeting of Scavenger Receptors Stabilin-1 and Stabilin-2 Ameliorates Atherosclerosis by a Plasma Proteome Switch Mediating Monocyte/Macrophage Suppression. Circulation 2022; 146:1783-1799. [PMID: 36325910 DOI: 10.1161/circulationaha.121.058615] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND Scavenger receptors Stabilin-1 (Stab1) and Stabilin-2 (Stab2) are preferentially expressed by liver sinusoidal endothelial cells. They mediate the clearance of circulating plasma molecules controlling distant organ homeostasis. Studies suggest that Stab1 and Stab2 may affect atherosclerosis. Although subsets of tissue macrophages also express Stab1, hematopoietic Stab1 deficiency does not modulate atherogenesis. Here, we comprehensively studied how targeting Stab1 and Stab2 affects atherosclerosis. METHODS ApoE-KO mice were interbred with Stab1-KO and Stab2-KO mice and fed a Western diet. For antibody targeting, Ldlr-KO mice were also used. Unbiased plasma proteomics were performed and independently confirmed. Ligand binding studies comprised glutathione-S-transferase-pulldown and endocytosis assays. Plasma proteome effects on monocytes were studied by single-cell RNA sequencing in vivo, and by gene expression analyses of Stabilin ligand-stimulated and plasma-stimulated bone marrow-derived monocytes/macrophages in vitro. RESULTS Spontaneous and Western diet-associated atherogenesis was significantly reduced in ApoE-Stab1-KO and ApoE-Stab2-KO mice. Similarly, inhibition of Stab1 or Stab2 by monoclonal antibodies significantly reduced Western diet-associated atherosclerosis in ApoE-KO and Ldlr-KO mice. Although neither plasma lipid levels nor circulating immune cell numbers were decisively altered, plasma proteomics revealed a switch in the plasma proteome, consisting of 231 dysregulated proteins comparing wildtype with Stab1/2-single and Stab1/2-double KO, and of 41 proteins comparing ApoE-, ApoE-Stab1-, and ApoE-Stab2-KO. Among this broad spectrum of common, but also disparate scavenger receptor ligand candidates, periostin, reelin, and TGFBi (transforming growth factor, β-induced), known to modulate atherosclerosis, were independently confirmed as novel circulating ligands of Stab1/2. Single-cell RNA sequencing of circulating myeloid cells of ApoE-, ApoE-Stab1-, and ApoE-Stab2-KO mice showed transcriptomic alterations in patrolling (Ccr2-/Cx3cr1++/Ly6Clo) and inflammatory (Ccr2+/Cx3cr1+/Ly6Chi) monocytes, including downregulation of proatherogenic transcription factor Egr1. In wildtype bone marrow-derived monocytes/macrophages, ligand exposure alone did not alter Egr1 expression in vitro. However, exposure to plasma from ApoE-Stab1-KO and ApoE-Stab2-KO mice showed a reverted proatherogenic macrophage activation compared with ApoE-KO plasma, including downregulation of Egr1 in vitro. CONCLUSIONS Inhibition of Stab1/Stab2 mediates an anti-inflammatory switch in the plasma proteome, including direct Stabilin ligands. The altered plasma proteome suppresses both patrolling and inflammatory monocytes and, thus, systemically protects against atherogenesis. Altogether, anti-Stab1- and anti-Stab2-targeted therapies provide a novel approach for the future treatment of atherosclerosis.
Collapse
Affiliation(s)
- Calin-Petru Manta
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Thomas Leibing
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Section of Clinical and Molecular Dermatology (T.L., M.A., J.K., C.K., Y.X., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Mirco Friedrich
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Department of Neurology, MCTN (M.F., M.P.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (M.F., M.P.)
| | - Hendrik Nolte
- European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Institute for Genetics and CECAD, University of Cologne, Germany (H.N., M.K.).,Max Planck Institute for Biology of Ageing, Cologne, Germany (H.N.)
| | - Monica Adrian
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Section of Clinical and Molecular Dermatology (T.L., M.A., J.K., C.K., Y.X., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Kai Schledzewski
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Jessica Krzistetzko
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Section of Clinical and Molecular Dermatology (T.L., M.A., J.K., C.K., Y.X., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Christof Kirkamm
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Section of Clinical and Molecular Dermatology (T.L., M.A., J.K., C.K., Y.X., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Christian David Schmid
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Yannick Xi
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Section of Clinical and Molecular Dermatology (T.L., M.A., J.K., C.K., Y.X., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Ana Stojanovic
- European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Department of Immunobiochemistry, Mannheim Institute for Innate Immunoscience, MI3 (A.S., A.C.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Sarah Tonack
- Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Bad Nauheim, Germany (S.T., S.O., M.K.)
| | - Carolina de la Torre
- Centre for Medical Research (ZMF) (C.d.l.T.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Seddik Hammad
- Department of Medicine II (S.H.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Stefan Offermanns
- Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Bad Nauheim, Germany (S.T., S.O., M.K.)
| | - Marcus Krüger
- Institute for Genetics and CECAD, University of Cologne, Germany (H.N., M.K.).,Max Planck Institute for Heart and Lung Research, Department of Pharmacology, Bad Nauheim, Germany (S.T., S.O., M.K.)
| | - Adelheid Cerwenka
- European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Department of Immunobiochemistry, Mannheim Institute for Innate Immunoscience, MI3 (A.S., A.C.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Michael Platten
- European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Department of Neurology, MCTN (M.F., M.P.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (M.F., M.P.)
| | - Sergij Goerdt
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| | - Cyrill Géraud
- Department of Dermatology, Venereology, and Allergology (C.-P.M., T.L., M.A., K.S., J.K., C.K., C.D.S., Y.X., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,Section of Clinical and Molecular Dermatology (T.L., M.A., J.K., C.K., Y.X., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany.,European Center for Angioscience (ECAS) (C.-P.M., T.L., M.F., M.A., K.S., J.K., C.K., C.D.S., Y.X., A.S., A.C., M.P., S.G., C.G.), University Medical Center and Medical Faculty Mannheim, Heidelberg University, Germany
| |
Collapse
|
5
|
Xin Y, Li S, Liu H, Liu B. Periostin and TNF-α expression levels in peripheral blood of patients with acute cerebral infarction combined with obstructive sleep apnea syndrome and their predictive value for clinical prognosis. BMC Neurol 2022; 22:358. [PMID: 36127647 PMCID: PMC9487120 DOI: 10.1186/s12883-022-02885-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 09/12/2022] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE To detect the expression levels of periostin and tumour necrosis factor-α (TNF-α) in patients with acute cerebral infarction (ACI) combined with obstructive sleep apnea syndrome (OSAS) and to investigate their predictive value for clinical prognosis. METHODS In this case‒control study, serum periostin and TNF-α levels were measured using ELISA, and patients were scored on the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS). Receiver operating characteristic curve(ROC) were generated to analyse the effect of peripheral blood periostin and TNF-α levels on poor prognosis. RESULTS NIHSS score, mRS score and peripheral blood periostin and TNF-α levels were higher in the observation group than in the control group (P < 0.001); serum periostin and TNF-α levels were positively correlated with the NIHSS score and mRS score (P < 0.001). Serum periostin and TNF-α levels were higher in patients with a poor prognosis than in those with a favourable prognosis (P < 0.001); the area under curve (AUC) values for the diagnosis of poor prognosis based on TNF-α, periostin or both factors were 0.868 (95% CI: 0.781-0.954), 0.834 (95% CI: 0.734-0.934), and 0.875 (95% CI: 0.792 ~ 0.958), with sensitivities of 0.654, 0.846, and 0.654 and specificities of 0.944, 0.750, and 0.917, respectively. CONCLUSION Patients with ACI combined with OSAS have elevated peripheral blood periostin and TNF-α levels, and the combination of these two factors has high predictive value for poor prognosis.
Collapse
Affiliation(s)
- Yu Xin
- Department of Neurology, The First Affiliated Hospital of Baotou Medical College, Baotou, 014010, Inner Mongolia, China
| | - Shuai Li
- Department of Neurology, The First Affiliated Hospital of Baotou Medical College, Baotou, 014010, Inner Mongolia, China
| | - Huimin Liu
- Department of Neurology, The First Affiliated Hospital of Baotou Medical College, Baotou, 014010, Inner Mongolia, China
| | - Bo Liu
- Department of Neurology, The First Affiliated Hospital of Baotou Medical College, Baotou, 014010, Inner Mongolia, China.
| |
Collapse
|
6
|
Lu Y, Dimitrov L, Chen SH, Bielak LF, Bis JC, Feitosa MF, Lu L, Kavousi M, Raffield LM, Smith AV, Wang L, Weiss S, Yao J, Zhu J, Gudmundsson EF, Gudmundsdottir V, Bos D, Ghanbari M, Ikram MA, Hwang SJ, Taylor KD, Budoff MJ, Gíslason GK, O’Donnell CJ, An P, Franceschini N, Freedman BI, Fu YP, Guo X, Heiss G, Kardia SL, Wilson JG, Langefeld CD, Schminke U, Uitterlinden AG, Lange LA, Peyser PA, Gudnason VG, Psaty BM, Rotter JI, Bowden DW, Ng MCY. Multiethnic Genome-Wide Association Study of Subclinical Atherosclerosis in Individuals With Type 2 Diabetes. CIRCULATION. GENOMIC AND PRECISION MEDICINE 2021; 14:e003258. [PMID: 34241534 PMCID: PMC8435075 DOI: 10.1161/circgen.120.003258] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 06/20/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND Coronary artery calcification (CAC) and carotid artery intima-media thickness (cIMT) are measures of subclinical atherosclerosis in asymptomatic individuals and strong risk factors for cardiovascular disease. Type 2 diabetes (T2D) is an independent cardiovascular disease risk factor that accelerates atherosclerosis. METHODS We performed meta-analyses of genome-wide association studies in up to 2500 T2D individuals of European ancestry (EA) and 1590 T2D individuals of African ancestry with or without exclusion of prevalent cardiovascular disease, for CAC measured by cardiac computed tomography, and 3608 individuals of EA and 838 individuals of African ancestry with T2D for cIMT measured by ultrasonography within the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium. RESULTS We replicated 2 loci (rs9369640 and rs9349379 near PHACTR1 and rs10757278 near CDKN2B) for CAC and one locus for cIMT (rs7412 and rs445925 near APOE-APOC1) that were previously reported in the general EA populations. We identified one novel CAC locus (rs8000449 near CSNK1A1L/LINC00547/POSTN at 13q13.3) at P=2.0×10-8 in EA. No additional loci were identified with the meta-analyses of EA and African ancestry. The expression quantitative trait loci analysis with nearby expressed genes derived from arterial wall and metabolic tissues from the Genotype-Tissue Expression project pinpoints POSTN, encoding a matricellular protein involved in bone formation and bone matrix organization, as the potential candidate gene at this locus. In addition, we found significant associations (P<3.1×10-4) for 3 previously reported coronary artery disease loci for these subclinical atherosclerotic phenotypes (rs2891168 near CDKN2B-AS1 and rs11170820 near FLJ12825 for CAC, and rs7412 near APOE for cIMT). CONCLUSIONS Our results provide potential biological mechanisms that could link CAC and cIMT to increased cardiovascular disease risk in individuals with T2D.
Collapse
Affiliation(s)
- Yingchang Lu
- Vanderbilt Genetic Institute, Division of Genetic Medicine,
Vanderbilt University Medical Center, Nashville, TN
| | - Latchezar Dimitrov
- Center for Precision Medicine, Wake Forest School of
Medicine, Winston-Salem, NC
| | - Shyh-Huei Chen
- Department of Biostatistics & Data Science, Wake Forest
School of Medicine, Winston-Salem, NC
| | - Lawrence F. Bielak
- Department of Epidemiology, School of Public Health,
University of Michigan, Ann Arbor, MI
| | - Joshua C. Bis
- Cardiovascular Health Research Unit, Departments of
Medicine, Epidemiology & Health Services, University of Washington, Seattle,
WA
| | - Mary F. Feitosa
- Division of Statistical Genomics, Department of Genetics,
Washington University School of Medicine, Farrell Learning Center, St Louis,
MO
| | - Lingyi Lu
- Department of Biostatistics & Data Science, Wake Forest
School of Medicine, Winston-Salem, NC
| | - Maryam Kavousi
- Department of Epidemiology, Erasmus Medical Centre,
Rotterdam, the Netherlands
| | - Laura M. Raffield
- Department of Genetics, University of North Carolina,
Chapel Hill, NC
| | - Albert V. Smith
- Faculty of Medicine, University of Iceland, Reykjavik &
Icelandic Heart Association, Kopavogur, Iceland & Department of Biostatistics,
School of Public Health, University of Michigan, Ann Arbor, MI
| | - Lihua Wang
- Division of Statistical Genomics, Department of Genetics,
Washington University School of Medicine, Farrell Learning Center, St Louis,
MO
| | - Stefan Weiss
- Interfaculty Institute for Genetics and Functional
Genomics, Department of Functional Genomics, University of Greifswald &
University Medicine Greifswald, Greifswald & DZHK (German Centre for
Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany
| | - Jie Yao
- The Institute for Translational Genomics and Population
Sciences & Department of Pediatrics, The Lundquist Institute for Biomedical
Innovation at Harbor-UCLA Medical Center, Torrance, CA
| | - Jiaxi Zhu
- Division of Statistical Genomics, Department of Genetics,
Washington University School of Medicine, Farrell Learning Center, St Louis,
MO
| | - Elias F. Gudmundsson
- Faculty of Medicine, University of Iceland, Reykjavik
& Icelandic Heart Association, Kopavogur, Iceland
| | - Valborg Gudmundsdottir
- Faculty of Medicine, University of Iceland, Reykjavik
& Icelandic Heart Association, Kopavogur, Iceland
| | - Daniel Bos
- Department of Epidemiology, Erasmus Medical Centre &
Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center
Rotterdam, Rotterdam, the Netherlands
| | - Mohsen Ghanbari
- Department of Epidemiology, Erasmus Medical Centre,
Rotterdam, the Netherlands
| | - M. Arfan Ikram
- Department of Epidemiology, Erasmus Medical Centre,
Rotterdam, the Netherlands
| | - Shih-Jen Hwang
- The Population Sciences Branch, Division of Intramural
Research, National Heart, Lung and Blood Institute, National Institutes of Health,
Bethesda, MD & The Framingham Heart Study, National Heart, Lung and Blood
Institute, National Institutes of Health, Framingham, MA
| | - Kent D. Taylor
- The Institute for Translational Genomics and Population
Sciences & Department of Pediatrics, The Lundquist Institute for Biomedical
Innovation at Harbor-UCLA Medical Center, Torrance, CA
| | - Matthew J. Budoff
- Division of Cardiology, Lundquist Institute at
Harbor-UCLA Medical Center, Torrance, CA
| | - Gauti K. Gíslason
- Faculty of Medicine, University of Iceland, Reykjavik
& Icelandic Heart Association, Kopavogur, Iceland
| | - Christopher J. O’Donnell
- VA Boston Healthcare System & Department of Medicine,
Brigham Women’s Hospital & Department of Medicine, Harvard Medical
School, Boston, MA
| | - Ping An
- Division of Statistical Genomics, Department of Genetics,
Washington University School of Medicine, Farrell Learning Center, St Louis,
MO
| | - Nora Franceschini
- Department of Epidemiology, University of North Carolina,
Chapel Hill, NC
| | - Barry I. Freedman
- Department of Internal Medicine, Wake Forest School of
Medicine, Winston-Salem, NC
| | - Yi-Ping Fu
- The Framingham Heart Study, National Heart, Lung and
Blood Institute, National Institutes of Health, Framingham, MA & Office of
Biostatistics Research, National Heart, Lung, and Blood Institute, National
Institutes of Health, Bethesda, MD
| | - Xiuqing Guo
- The Institute for Translational Genomics and Population
Sciences & Department of Pediatrics, The Lundquist Institute for Biomedical
Innovation at Harbor-UCLA Medical Center, Torrance, CA
| | - Gerardo Heiss
- Department of Epidemiology, University of North Carolina,
Chapel Hill, NC
| | - Sharon L.R. Kardia
- Department of Epidemiology, School of Public Health,
University of Michigan, Ann Arbor, MI
| | - James G. Wilson
- Department of Physiology and Biophysics, University of
Mississippi Medical Center, Jackson, MS & Department of Cardiology, Beth Israel
Deaconess Medical Center, Boston, MA
| | - Carl D. Langefeld
- Center for Precision Medicine & Department of
Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem,
NC
| | - Ulf Schminke
- Department of Neurology, University Medicine Greifswald,
Greifswald, Germany
| | - André G. Uitterlinden
- Department of Epidemiology, Erasmus Medical Centre &
Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam,
Rotterdam, the Netherlands
| | - Leslie A. Lange
- Division of Biomedical Informatics and Personalized
Medicine, School of Medicine, University of Colorado, Anschutz Medical Campus,
Aurora, CO
| | - Patricia A. Peyser
- Department of Epidemiology, School of Public Health,
University of Michigan, Ann Arbor, MI
| | - Vilmundur G. Gudnason
- Faculty of Medicine, University of Iceland, Reykjavik
& Icelandic Heart Association, Kopavogur, Iceland
| | - Bruce M. Psaty
- Departments of Epidemiology & Health Services,
University of Washington, Seattle, WA
| | - Jerome I. Rotter
- The Institute for Translational Genomics and Population
Sciences & Department of Pediatrics, The Lundquist Institute for Biomedical
Innovation at Harbor-UCLA Medical Center, Torrance, CA
| | - Donald W. Bowden
- Center for Precision Medicine & Department of
Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC
| | - Maggie CY Ng
- Vanderbilt Genetic Institute, Division of Genetic
Medicine, Vanderbilt University Medical Center, Nashville, TN & Center for
Precision Medicine, Wake Forest School of Medicine, Winston-Salem, NC
| |
Collapse
|
7
|
Zhu Y, Ji JJ, Wang XD, Sun XJ, Li M, Wei Q, Ren LQ, Liu NF. Periostin promotes arterial calcification through PPARγ-related glucose metabolism reprogramming. Am J Physiol Heart Circ Physiol 2021; 320:H2222-H2239. [PMID: 33834866 DOI: 10.1152/ajpheart.01009.2020] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Extracellular matrix (ECM) exerts a series of biological functions and contributes to almost 30% of the osteogenic process. Periostin is a secreted protein that can alter ECM remodeling in response to vascular injury. However, the role of periostin in vascular calcification has yet to be fully investigated. As found in this study, recombinant periostin accelerated the thoracic aortas calcification, increased the expression of glycolysis key enzymes, and disturbed the normal oxidative phosphorylation (OXPHOS) ex vivo, which could be alleviated by the peroxisome proliferation-activated receptor γ (PPARγ) agonist pioglitazone. In vascular smooth muscle cells (VSMCs), periostin promoted VSMC-osteoblastic phenotype transition and calcium deposition and suppressed PPARγ expression. Mechanistically, periostin caused overactivation of glycolysis and mitochondrial dysfunction in VSMCs as assessed by extracellular acidification rate, oxygen consumption rate, and mitochondrial respiratory chain complex activities. Targeted glycolysis inhibitors reduced mitochondrial calcium overload, apoptosis, and periostin-induced VSMCs calcification. PPARγ agonists preserved glycolysis and OXPHOS in the stimulated microenvironment and reversed periostin-promoted VSMC calcification. Furthermore, plasma periostin, lactate, and matrix Gla protein levels were measured in 274 patients undergoing computed tomography to determine coronary artery calcium score (Agatston score). Plasma periostin and lactate levels were both linked to an Agatston score in patients with coronary artery calcification (CAC). There was also a positive correlation between plasma periostin and lactate levels. This study suggests that downregulation of PPARγ is involved in the mechanism by which periostin accelerates arterial calcification partly through excessive glycolysis activation and unbalanced mitochondrial homeostasis.NEW & NOTEWORTHY Periostin caused arterial calcification, overactivated glycolysis, and damaged OXPHOS. PPARγ agonists alleviated periostin-promoted arterial calcification and corrected abnormal glycolysis and unbalanced mitochondrial homeostasis. There exists a relationship between periostin and lactate in patients with CAC.
Collapse
Affiliation(s)
- Yi Zhu
- Department of Cardiology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| | - Jing-Jing Ji
- Department of Cardiology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| | - Xiao-Dong Wang
- Department of Cardiology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| | - Xue-Jiao Sun
- Department of Cardiology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| | - Min Li
- Department of Cardiology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| | - Qin Wei
- Department of Cardiology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| | - Li-Qun Ren
- Department of Geriatrics, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| | - Nai-Feng Liu
- Department of Cardiology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, People's Republic of China
| |
Collapse
|
8
|
Sun XJ, Ma WQ, Zhu Y, Liu NF. POSTN promotes diabetic vascular calcification by interfering with autophagic flux. Cell Signal 2021; 83:109983. [PMID: 33744420 DOI: 10.1016/j.cellsig.2021.109983] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Revised: 03/10/2021] [Accepted: 03/13/2021] [Indexed: 12/27/2022]
Abstract
Autophagy is a lysosomal degradative process that is closely related to the pathogenesis of vascular calcification. Recent evidence suggests that periostin (POSTN) is a unique extracellular matrix protein that is associated with diabetic vascular complications. The aim of current study is to investigate the role of POSTN in diabetic vascular calcification and the underlying mechanisms. Results showed that POSTN was highly upregulated in both calcified arteries of diabetic rats and AGEs-BSA mediated vascular smooth muscle cell (VSMC) calcification. POSTN blocked autophagic flux during the diabetic calcification process, as evidenced by increased protein expression of Beclin1, LC3-II, and P62, as well as the co-localization of LC3-II and LAMP1. Inhibition of POSTN alleviated AGEs-BSA-induced autophagic flux blockade, thereby attenuating AGEs-BSA-induced VSMC calcification. Mechanistically, the upregulation of POSTN impaired the fusion of autophagosomes and lysosome and resulted in the autophagic flux blockade in AGEs-BSA-treated VSMC. Furthermore, this autophagic blockade was intracellular ROS-dependent. In summary, this study uncovered a novel mechanism of POSTN in autophagy regulation of diabetic vascular calcification.
Collapse
Affiliation(s)
- Xue-Jiao Sun
- Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing 210009, PR China
| | - Wen-Qi Ma
- Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing 210009, PR China
| | - Yi Zhu
- Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing 210009, PR China
| | - Nai-Feng Liu
- Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao, Nanjing 210009, PR China.
| |
Collapse
|
9
|
Xiao H, Chen J, Duan L, Li S. Role of emerging vitamin K‑dependent proteins: Growth arrest‑specific protein 6, Gla‑rich protein and periostin (Review). Int J Mol Med 2021; 47:2. [PMID: 33448308 PMCID: PMC7834955 DOI: 10.3892/ijmm.2020.4835] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Accepted: 10/21/2020] [Indexed: 01/27/2023] Open
Abstract
Vitamin K‑dependent proteins (VKDPs) are a group of proteins that need vitamin K to conduct carboxylation. Thus far, scholars have identified a total of 17 VKDPs in the human body. In this review, we summarize three important emerging VKDPs: Growth arrest‑specific protein 6 (Gas 6), Gla‑rich protein (GRP) and periostin in terms of their functions in physiological and pathological conditions. As examples, carboxylated Gas 6 and GRP effectively protect blood vessels from calcification, Gas 6 protects from acute kidney injury and is involved in chronic kidney disease, GRP contributes to bone homeostasis and delays the progression of osteoarthritis, and periostin is involved in all phases of fracture healing and assists myocardial regeneration in the early stages of myocardial infarction. However, periostin participates in the progression of cardiac fibrosis, idiopathic pulmonary fibrosis and airway remodeling of asthma. In addition, we discuss the relationship between vitamin K, VKDPs and cancer, and particularly the carboxylation state of VKDPs in cancer.
Collapse
Affiliation(s)
- Huiyu Xiao
- Department of Physiology, Dalian Medical University, Dalian, Liaoning 116044
| | - Jiepeng Chen
- Sungen Bioscience Co., Ltd., Shantou, Guangdong 515071, P.R. China
| | - Lili Duan
- Sungen Bioscience Co., Ltd., Shantou, Guangdong 515071, P.R. China
| | - Shuzhuang Li
- Department of Physiology, Dalian Medical University, Dalian, Liaoning 116044
| |
Collapse
|
10
|
Smirne C, Mulas V, Barbaglia MN, Mallela VR, Minisini R, Barizzone N, Burlone ME, Pirisi M, Grossini E. Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease. Diagnostics (Basel) 2020; 10:E1003. [PMID: 33255560 PMCID: PMC7760606 DOI: 10.3390/diagnostics10121003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 11/18/2020] [Accepted: 11/23/2020] [Indexed: 11/24/2022] Open
Abstract
Circulating periostin has been suggested as a possible biomarker in non-alcoholic fatty liver disease (NAFLD) in Asian studies. In the present study, we aimed to test its still controversial relevance in a Caucasian population. In patients with histologically-proven NAFLD (N. = 74; 10 with hepatocellular carcinoma, HCC) plasma periostin concentrations were analyzed. POSTN haplotype analysis was based on rs9603226, rs3829365, and rs1029728. Hepatitis C patients (N. = 81, 7 HCC) and healthy subjects (N. = 27) were used as controls. The median plasma periostin concentration was 11.6 ng/mL without differences amongst groups; it was not influenced by age, liver fibrosis or steatosis. However, possession of haplotype two (rs9603226 = G, rs3829365 = C, rs1028728 = A) was associated with lower circulating periostin compared to other haplotypes. Moreover, periostin was higher in HCC patients. At multivariate analysis, HCC remained the only predictor of high periostin. In conclusion, plasma periostin concentrations in Caucasians NAFLD patients are not influenced by the degree of liver disease, but are significantly higher in HCC. Genetically-determined differences may account for some of the variability. These data suggest extreme caution in predicting a possible future role of periostin antagonists as a rational therapeutic alternative for NAFLD, but show a potential periostin role in the management of NAFLD-associated HCC.
Collapse
Affiliation(s)
- Carlo Smirne
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| | - Violante Mulas
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| | - Matteo Nazzareno Barbaglia
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| | - Venkata Ramana Mallela
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| | - Rosalba Minisini
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| | - Nadia Barizzone
- Department of Health Sciences, Università’ del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy;
| | - Michela Emma Burlone
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| | - Mario Pirisi
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| | - Elena Grossini
- Department of Translational Medicine, Università del Piemonte Orientale, via Solaroli, 17, 28100 Novara, Italy; (V.M.); (M.N.B.); (V.R.M.); (R.M.); (M.E.B.); (M.P.); (E.G.)
| |
Collapse
|
11
|
Azharuddin M, Adil M, Ghosh P, Kapur P, Sharma M. Periostin as a novel biomarker of cardiovascular disease: A systematic evidence landscape of preclinical and clinical studies. J Evid Based Med 2019; 12:325-336. [PMID: 31769219 DOI: 10.1111/jebm.12368] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 08/17/2019] [Accepted: 11/03/2019] [Indexed: 11/27/2022]
Abstract
BACKGROUND Periostin is a matricellular protein, expressed in various normal adult and fetal tissues. Recently, elevated periostin levels have been reported in heart failure, coronary artery disease, and stroke. However, there is lack of clinical studies to clarify the prognostic significance of systemic periostin levels in cardiovascular diseases (CVDs). The aim of the study was to perform a systematic review of published evidence on periostin and CVDs, and to clarify the diagnostic and prognostic significance of systemic periostin levels in CVDs. METHODS A systematic search on PubMed was performed to identify relevant articles from inception to December 2018. The eligible studies evaluating the periostin expression and periostin levels in animal and human studies. RESULTS A total of 24 relevant studies, including both animal and human data, were included. Periostin is significantly observed in myocardium tissue of failing hearts compared with control, and is also expressed in atherosclerotic plaques. Systemic periostin levels were significantly correlated with cardiac function and severity of CVD in several studies. A clinical study also observed positive correlation between periostin and N-terminal pro b-type natriuretic peptide (NT-proBNP), highly sensitive troponin (hsTnT), and ST2 cardiac biomarker. Studies reported limited adjustment for potential confounders. CONCLUSIONS The evidence of current review support potential role of periostin in the pathophysiology of CVD. However, scarcity of data regarding the clinical use of periostin levels in the current management of CVDs further creates room for the future investigation. Therefore, further studies warrant to clarify its potential role, if any, as a novel cardiac biomarker.
Collapse
Affiliation(s)
- Md Azharuddin
- Division of Pharmacology, Department of Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
| | - Mohammad Adil
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
| | - Pinaki Ghosh
- Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth, Pune, India
| | - Prem Kapur
- Department of Medicine, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, India
| | - Manju Sharma
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
| |
Collapse
|
12
|
Zhong H, Li X, Zhang J, Wu X. Overexpression of periostin is positively associated with gastric cancer metastasis through promoting tumor metastasis and invasion. J Cell Biochem 2019; 120:9927-9935. [PMID: 30637809 DOI: 10.1002/jcb.28275] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Accepted: 10/24/2018] [Indexed: 12/18/2022]
Abstract
BACKGROUND Gastric tumors generally have a poor prognosis and molecular markers to improve early detection and predict outcomes are greatly needed. The present study reports that periostin (POSTN), a secretory protein that can alter the remodeling of the extracellular matrix, is highly expressed in gastric tumors. MATERIALS AND METHODS Gastric tissues were collected from patients at the Department of Thoracic Surgery/Huiqiao Medical Center, Nanfang Hospital, Southern Medical University. These patients provided an informed consent and were approved by the institute. Normal, cancer, and metastatic gastric tissues from lymph nodes and tissues adjacent to the tumor were collected from patients diagnosed with gastric cancer. RESULTS Periostin expression gradually increased as the risk grade of the NIH classification increased, and this was closely correlated with disease-free survival and overall survival. Compared with adjacent normal gastric mucosa tissues, protein expression of POSTN in gastric cancer tissues and metastases was significantly higher by immunohistochemistry and Western blot analysis. In addition, POSTN was upregulated in advanced gastric cancer tissues than in early gastric cancer tissues. Moreover, the ectopic expression of POSTN in the immortalized human gastric cell line could increase the metastasis and invasion of gastric cancer cells. CONCLUSION The present results could establish the significance of POSTN in driving oncogenesis and metastasis in gastric tumors, with implications for its potential use as a diagnostic or prognostic biomarker, and as a candidate therapeutic target.
Collapse
Affiliation(s)
- Hai Zhong
- Department of Thoracic Surgery, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.,Department of Cardiothoracic Surgery, The second Hospital of Yinzhou District, Ningbo, People's Republic of China
| | - Xiang Li
- Department of Thoracic Surgery, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China
| | - Junhua Zhang
- Departmentof Operating Room, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China
| | - Xu Wu
- Department of Thoracic Surgery, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China
| |
Collapse
|
13
|
Chaudhary R, Walder KR, Hagemeyer CE, Kanwar JR. Psammomys obesus: a Natural Diet-Controlled Model for Diabetes and Cardiovascular Diseases. Curr Atheroscler Rep 2018; 20:46. [PMID: 30019290 DOI: 10.1007/s11883-018-0746-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
PURPOSE OF REVIEW This review specifically summarises and reports terrestrial mammals of the gerbil subfamily, known as Israeli sand rats or Psammomys obesus (P. obesus) as a diet-controlled, unique, polygenic rodent model for research in the areas of obesity, type 2 diabetes, and cardiovascular diseases. The animal model closely mimics phenotypic and pathophysiological resemblance with human populations. RECENT FINDINGS The physiological status and biochemical composition in P. obesus can be manipulated effectively by controlling its nutritional intake, making it a natural model for cardiovascular and diabetic research. Humans exhibit remarkable disparity in physiology and pathology, which are inter-dependent factors. However, variations in these factors in most animal models currently being used for cardiovascular/diabetes research are insignificant. Consequently, it is a necessity to identify and develop animal models exhibiting physiological variations mimicking human pathological conditions. We have compiled research developments conducted with this rodent model manifesting pathophysiology, closely mimicking that in human beings, thereby enabling better translation of novel therapeutic and diagnostic discoveries.
Collapse
Affiliation(s)
- Rajneesh Chaudhary
- Australian Centre for Blood Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash University, Monash AMREP building, Level 2, Walkway, via The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
- School of Medicine, Centre for Molecular and Medical Research, Faculty of Health, Deakin University, School of Medicine, Deakin University - 75 Pigdons Rd, Geelong, VIC, 3216, Australia.
| | - Ken R Walder
- School of Medicine, Centre for Molecular and Medical Research, Faculty of Health, Deakin University, School of Medicine, Deakin University - 75 Pigdons Rd, Geelong, VIC, 3216, Australia
| | - Christoph E Hagemeyer
- Australian Centre for Blood Diseases, Faculty of Medicine, Nursing and Health Sciences, Monash University, Monash AMREP building, Level 2, Walkway, via The Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia
| | - Jagat R Kanwar
- School of Medicine, Centre for Molecular and Medical Research, Faculty of Health, Deakin University, School of Medicine, Deakin University - 75 Pigdons Rd, Geelong, VIC, 3216, Australia
| |
Collapse
|
14
|
Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CTJ, Matthews JG, Arron JR. Roles of Periostin in Respiratory Disorders. Am J Respir Crit Care Med 2017; 193:949-56. [PMID: 26756066 DOI: 10.1164/rccm.201510-2032pp] [Citation(s) in RCA: 128] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Periostin is a matricellular protein that has been implicated in many disease states. It interacts with multiple signaling cascades to modulate the expression of downstream genes that regulate cellular interactions within the extracellular matrix. This review focuses on the role of periostin in respiratory diseases, including asthma and idiopathic pulmonary fibrosis, and its potential to help guide treatment or assess prognosis. Epithelial injury is a common feature of many respiratory diseases, resulting in the secretion, among others, of periostin, which is subsequently involved in airway remodeling and other aspects of pulmonary pathophysiology. In asthma, periostin is recognized as a biomarker of type 2 inflammation; POSTN gene expression is up-regulated in bronchial epithelial cells by IL-13 and IL-4. Serum periostin has been evaluated for the identification of patients with increased clinical benefit from treatment with anti-IL-13 (lebrikizumab, tralokinumab) and anti-IgE (omalizumab) therapy and may be prognostic for increased risk of asthma exacerbations and progressive lung function decline. Furthermore, in asthma, periostin may regulate subepithelial fibrosis and mucus production and may serve as a systemic biomarker of eosinophilic airway inflammation. Periostin is also highly expressed in the lungs of patients with idiopathic pulmonary fibrosis, and its serum levels may predict clinical progression. Overall, periostin contributes to multiple pathogenic processes across respiratory diseases, and peripheral blood levels of periostin may have utility as a biomarker of treatment response and disease progression.
Collapse
Affiliation(s)
- Kenji Izuhara
- 1 Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan
| | - Simon J Conway
- 2 Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana
| | - Bethany B Moore
- 3 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, and.,4 Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan
| | - Hisako Matsumoto
- 5 Department of Respiratory Medicine, Kyoto University, Kyoto, Japan; and
| | - Cecile T J Holweg
- 6 Genentech Inc. (a member of the Roche Group), South San Francisco, California
| | - John G Matthews
- 6 Genentech Inc. (a member of the Roche Group), South San Francisco, California
| | - Joseph R Arron
- 6 Genentech Inc. (a member of the Roche Group), South San Francisco, California
| |
Collapse
|
15
|
Ayyadevara S, Mercanti F, Wang X, Mackintosh SG, Tackett AJ, Prayaga SVS, Romeo F, Shmookler Reis RJ, Mehta JL. Age- and Hypertension-Associated Protein Aggregates in Mouse Heart Have Similar Proteomic Profiles. Hypertension 2016; 67:1006-13. [PMID: 26975704 DOI: 10.1161/hypertensionaha.115.06849] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Accepted: 02/08/2016] [Indexed: 12/19/2022]
Abstract
Neurodegenerative diseases are largely defined by protein aggregates in affected tissues. Aggregates contain some shared components as well as proteins thought to be specific for each disease. Aggregation has not previously been reported in the normal, aging heart or the hypertensive heart. Detergent-insoluble protein aggregates were isolated from mouse heart and characterized on 2-dimensional gels. Their levels increased markedly and significantly with aging and after sustained angiotensin II-induced hypertension. Of the aggregate components identified by high-resolution proteomics, half changed in abundance with age (392/787) or with sustained hypertension (459/824), whereas 30% (273/901) changed concordantly in both, each P<0.05. One fifth of these proteins were previously associated with age-progressive neurodegenerative or cardiovascular diseases, or both (eg, ApoE, ApoJ, ApoAIV, clusterin, complement C3, and others involved in stress-response and protein-homeostasis pathways). Because fibrosis is a characteristic of both aged and hypertensive hearts, we posited that aging of fibroblasts may contribute to the aggregates observed in cardiac tissue. Indeed, as cardiac myofibroblasts "senesced" (approached their replicative limit) in vitro, they accrued aggregates with many of the same constituent proteins observed in vivo during natural aging or sustained hypertension. In summary, we have shown for the first time that compact (detergent-insoluble) protein aggregates accumulate during natural aging, chronic hypertension, and in vitro myofibroblast senescence, sharing many common proteins. Thus, aggregates that arise from disparate causes (aging, hypertension, and replicative senescence) may have common underlying mechanisms of accrual.
Collapse
Affiliation(s)
- Srinivas Ayyadevara
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.).
| | - Federico Mercanti
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.)
| | - Xianwei Wang
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.)
| | - Samuel G Mackintosh
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.)
| | - Alan J Tackett
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.)
| | - Sastry V S Prayaga
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.)
| | - Francesco Romeo
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.)
| | - Robert J Shmookler Reis
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.).
| | - Jawahar L Mehta
- From the Central Arkansas Veterans Healthcare System, Little Rock (S.A., F.M., X.W., R.J.S.R., J.L.M.); Department of Geriatrics (S.A., R.J.S.R.), Division of Cardiology (F.M., X.W., S.V.S.P., J.L.M.), and Department of Biochemistry and Molecular Biology (S.G.M., A.J.T., R.J.S.R.), University of Arkansas for Medical Sciences (UAMS), Little Rock; and Department of Cardiology, University of Rome "Tor Vergata", Rome, Italy (F.M., F.R.).
| |
Collapse
|
16
|
Schwanekamp JA, Lorts A, Vagnozzi RJ, Vanhoutte D, Molkentin JD. Deletion of Periostin Protects Against Atherosclerosis in Mice by Altering Inflammation and Extracellular Matrix Remodeling. Arterioscler Thromb Vasc Biol 2015; 36:60-8. [PMID: 26564821 DOI: 10.1161/atvbaha.115.306397] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 10/29/2015] [Indexed: 12/20/2022]
Abstract
OBJECTIVE Periostin is a secreted protein that can alter extracellular matrix remodeling in response to tissue injury. However, the functional role of periostin in the development of atherosclerotic plaques has yet to be described despite its observed induction in diseased vessels and presence in the serum. APPROACH AND RESULTS Hyperlipidemic, apolipoprotein E-null mice (ApoE(-/) (-)) were crossed with periostin (Postn(-/-)) gene-deleted mice and placed on a high-fat diet for 6 or 14 weeks to induce atherosclerosis. En face analysis of aortas showed significantly decreased lesion areas of ApoE(-/-) Postn(-/-) mice compared with ApoE(-/-) mice, as well as a reduced inflammatory response with less macrophage content. Moreover, diseased aortas from ApoE(-/-) Postn(-/-) mice displayed a disorganized extracellular matrix with less collagen cross linking and smaller fibrotic caps, as well as increased matrix metalloproteinase-2, metalloproteinase-13, and procollagen-lysine, 2-oxoglutarate 5-dioxygenase-1 mRNA expression. Furthermore, the loss of periostin was associated with a switch in vascular smooth muscle cells toward a more proliferative and synthetic phenotype. Mechanistically, the loss of periostin reduced macrophage recruitment by transforming growth factor-β in cellular migration assays. CONCLUSIONS These are the first genetic data detailing the function of periostin as a regulator of atherosclerotic lesion formation and progression. The data suggest that periostin could be a therapeutic target for atherosclerotic plaque formation through modulation of the immune response and extracellular matrix remodeling.
Collapse
MESH Headings
- Animals
- Aorta, Thoracic/immunology
- Aorta, Thoracic/metabolism
- Aorta, Thoracic/pathology
- Aortic Diseases/genetics
- Aortic Diseases/immunology
- Aortic Diseases/metabolism
- Aortic Diseases/pathology
- Aortic Diseases/prevention & control
- Apolipoproteins E/deficiency
- Apolipoproteins E/genetics
- Atherosclerosis/genetics
- Atherosclerosis/immunology
- Atherosclerosis/metabolism
- Atherosclerosis/pathology
- Atherosclerosis/prevention & control
- Cell Adhesion Molecules/deficiency
- Cell Adhesion Molecules/genetics
- Cell Movement
- Cell Proliferation
- Cells, Cultured
- Collagen/metabolism
- Diet, High-Fat
- Disease Models, Animal
- Disease Progression
- Extracellular Matrix/metabolism
- Gene Deletion
- Gene Expression Regulation
- Inflammation/genetics
- Inflammation/immunology
- Inflammation/metabolism
- Inflammation/pathology
- Inflammation/prevention & control
- Macrophages/metabolism
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Phenotype
- Plaque, Atherosclerotic
- RNA, Messenger/metabolism
- Signal Transduction
- Time Factors
- Vascular Remodeling
Collapse
Affiliation(s)
- Jennifer A Schwanekamp
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Angela Lorts
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Ronald J Vagnozzi
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Davy Vanhoutte
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH
| | - Jeffery D Molkentin
- From the Department of Pediatrics (J.A.S., A.L., R.J.V., D.V., J.D.M.) and Howard Hughes Medical Institute (J.D.M.), Cincinnati Children's Hospital Medical Center, University of Cincinnati, OH.
| |
Collapse
|
17
|
Scheiber D, Veulemans V, Horn P, Chatrou ML, Potthoff SA, Kelm M, Schurgers LJ, Westenfeld R. High-Dose Menaquinone-7 Supplementation Reduces Cardiovascular Calcification in a Murine Model of Extraosseous Calcification. Nutrients 2015; 7:6991-7011. [PMID: 26295257 PMCID: PMC4555157 DOI: 10.3390/nu7085318] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 07/30/2015] [Accepted: 08/06/2015] [Indexed: 12/12/2022] Open
Abstract
Cardiovascular calcification is prevalent in the aging population and in patients with chronic kidney disease (CKD) and diabetes mellitus, giving rise to substantial morbidity and mortality. Vitamin K-dependent matrix Gla-protein (MGP) is an important inhibitor of calcification. The aim of this study was to evaluate the impact of high-dose menaquinone-7 (MK-7) supplementation (100 µg/g diet) on the development of extraosseous calcification in a murine model. Calcification was induced by 5/6 nephrectomy combined with high phosphate diet in rats. Sham operated animals served as controls. Animals received high or low MK-7 diets for 12 weeks. We assessed vital parameters, serum chemistry, creatinine clearance, and cardiac function. CKD provoked increased aortic (1.3 fold; p < 0.05) and myocardial (2.4 fold; p < 0.05) calcification in line with increased alkaline phosphatase levels (2.2 fold; p < 0.01). MK-7 supplementation inhibited cardiovascular calcification and decreased aortic alkaline phosphatase tissue concentrations. Furthermore, MK-7 supplementation increased aortic MGP messenger ribonucleic acid (mRNA) expression (10-fold; p < 0.05). CKD-induced arterial hypertension with secondary myocardial hypertrophy and increased elastic fiber breaking points in the arterial tunica media did not change with MK-7 supplementation. Our results show that high-dose MK-7 supplementation inhibits the development of cardiovascular calcification. The protective effect of MK-7 may be related to the inhibition of secondary mineralization of damaged vascular structures.
Collapse
Affiliation(s)
- Daniel Scheiber
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf 40225, Germany.
| | - Verena Veulemans
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf 40225, Germany.
| | - Patrick Horn
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf 40225, Germany.
| | - Martijn L Chatrou
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht 6229 ER, The Netherlands.
| | - Sebastian A Potthoff
- Department of Nephrology, University Duesseldorf, Medical Faculty, Duesseldorf 40225, Germany.
| | - Malte Kelm
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf 40225, Germany.
- Cardiovascular Research Institute Duesseldorf, University Duesseldorf, Medical Faculty, Duesseldorf 40225, Germany.
| | - Leon J Schurgers
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht 6229 ER, The Netherlands.
| | - Ralf Westenfeld
- Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Duesseldorf, Duesseldorf 40225, Germany.
| |
Collapse
|
18
|
Nurnberg ST, Cheng K, Raiesdana A, Kundu R, Miller CL, Kim JB, Arora K, Carcamo-Oribe I, Xiong Y, Tellakula N, Nanda V, Murthy N, Boisvert WA, Hedin U, Perisic L, Aldi S, Maegdefessel L, Pjanic M, Owens GK, Tallquist MD, Quertermous T. Coronary Artery Disease Associated Transcription Factor TCF21 Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap. PLoS Genet 2015; 11:e1005155. [PMID: 26020946 PMCID: PMC4447275 DOI: 10.1371/journal.pgen.1005155] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 03/18/2015] [Indexed: 01/10/2023] Open
Abstract
Recent genome wide association studies have identified a number of genes that contribute to the risk for coronary heart disease. One such gene, TCF21, encodes a basic-helix-loop-helix transcription factor believed to serve a critical role in the development of epicardial progenitor cells that give rise to coronary artery smooth muscle cells (SMC) and cardiac fibroblasts. Using reporter gene and immunolocalization studies with mouse and human tissues we have found that vascular TCF21 expression in the adult is restricted primarily to adventitial cells associated with coronary arteries and also medial SMC in the proximal aorta of mouse. Genome wide RNA-Seq studies in human coronary artery SMC (HCASMC) with siRNA knockdown found a number of putative TCF21 downstream pathways identified by enrichment of terms related to CAD, including “vascular disease,” “disorder of artery,” and “occlusion of artery,” as well as disease-related cellular functions including “cellular movement” and “cellular growth and proliferation.” In vitro studies in HCASMC demonstrated that TCF21 expression promotes proliferation and migration and inhibits SMC lineage marker expression. Detailed in situ expression studies with reporter gene and lineage tracing revealed that vascular wall cells expressing Tcf21 before disease initiation migrate into vascular lesions of ApoE-/- and Ldlr-/- mice. While Tcf21 lineage traced cells are distributed throughout the early lesions, in mature lesions they contribute to the formation of a subcapsular layer of cells, and others become associated with the fibrous cap. The lineage traced fibrous cap cells activate expression of SMC markers and growth factor receptor genes. Taken together, these data suggest that TCF21 may have a role regulating the differentiation state of SMC precursor cells that migrate into vascular lesions and contribute to the fibrous cap and more broadly, in view of the association of this gene with human CAD, provide evidence that these processes may be a mechanism for CAD risk attributable to the vascular wall. Coronary artery disease (CAD) is responsible for the majority of deaths in the Western world, and is due in part to environmental and metabolic factors. However, half of the risk for developing heart disease is genetically predetermined. Genome-wide association studies in human populations have identified over 100 sites in the genome that appear to be associated with CAD, however, the mechanisms by which variation in these regions are responsible for predisposition to CAD remain largely unknown. We have begun to study a gene that contributes to CAD risk, the TCF21 gene. Through genomic studies we show that this gene is involved in processes related to alterations in vascular gene expression, and in particular those related to the smooth muscle cell biology. With cell culture models, we show that TCF21 regulates the differentiation state of this cell type, which is believed critical for vascular disease. Using mouse genetic models of atherosclerotic vascular disease we provide evidence that this gene is expressed in precursor cells that migrate into the disease lesions and contribute to the formation of the fibrous cap that is believed to stabilize these lesions and prevent heart attacks.
Collapse
Affiliation(s)
- Sylvia T. Nurnberg
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Karen Cheng
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Azad Raiesdana
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Ramendra Kundu
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Clint L. Miller
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Juyong B. Kim
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Komal Arora
- Department of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America
| | - Ivan Carcamo-Oribe
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Yiqin Xiong
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Nikhil Tellakula
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Vivek Nanda
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Nikitha Murthy
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - William A. Boisvert
- Department of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America
| | - Ulf Hedin
- Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
| | - Ljubica Perisic
- Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
| | - Silvia Aldi
- Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
| | | | - Milos Pjanic
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
| | - Gary K. Owens
- Department of Molecular Physiology and Biological Physics, University of Virginia School of Medicine, Charlottesville, Virginia, United States of America
| | - Michelle D. Tallquist
- Department of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America
| | - Thomas Quertermous
- Department of Medicine, Cardiovascular Research Institute, Stanford University School of Medicine, Stanford, California, United States of America
- * E-mail:
| |
Collapse
|
19
|
Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 2014; 37:150-6. [DOI: 10.1016/j.matbio.2014.04.007] [Citation(s) in RCA: 124] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2014] [Revised: 04/28/2014] [Accepted: 04/28/2014] [Indexed: 02/06/2023]
|
20
|
Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G, Arron JR, Holweg CTJ, Kudo A. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 2014; 71:1279-88. [PMID: 24146092 PMCID: PMC3949008 DOI: 10.1007/s00018-013-1494-y] [Citation(s) in RCA: 275] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 10/04/2013] [Accepted: 10/07/2013] [Indexed: 12/22/2022]
Abstract
Periostin, also termed osteoblast-specific factor 2, is a matricellular protein with known functions in osteology, tissue repair, oncology, cardiovascular and respiratory systems, and in various inflammatory settings. However, most of the research to date has been conducted in divergent and circumscribed areas meaning that the overall understanding of this intriguing molecule remains fragmented. Here, we integrate the available evidence on periostin expression, its normal role in development, and whether it plays a similar function during pathologic repair, regeneration, and disease in order to bring together the different research fields in which periostin investigations are ongoing. In spite of the seemingly disparate roles of periostin in health and disease, tissue remodeling as a response to insult/injury is emerging as a common functional denominator of this matricellular molecule. Periostin is transiently upregulated during cell fate changes, either physiologic or pathologic. Combining observations from various conditions, a common pattern of events can be suggested, including periostin localization during development, insult and injury, epithelial-mesenchymal transition, extracellular matrix restructuring, and remodeling. We propose mesenchymal remodeling as an overarching role for the matricellular protein periostin, across physiology and disease. Periostin may be seen as an important structural mediator, balancing appropriate versus inappropriate tissue adaption in response to insult/injury.
Collapse
Affiliation(s)
- Simon J. Conway
- Program in Developmental Biology and Neonatal Medicine, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN USA
| | - Kenji Izuhara
- Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan
| | - Yasusei Kudo
- Department of Oral Molecular Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Judith Litvin
- Department of Anatomy and Cell Biology, Temple University School of Medicine, Philadelphia, PA USA
| | - Roger Markwald
- Department of Cell Biology and Anatomy, Medical University of South Carolina, Charleston, SC USA
| | - Gaoliang Ouyang
- State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, China
| | | | | | - Akira Kudo
- Department of Biological Information, Tokyo Institute of Technology, 4259 B-33, Nagatsuta, Midori-ku, Yokohama 226-8501 Japan
| |
Collapse
|
21
|
Morris AH, Kyriakides TR. Matricellular proteins and biomaterials. Matrix Biol 2014; 37:183-91. [PMID: 24657843 DOI: 10.1016/j.matbio.2014.03.002] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 03/12/2014] [Accepted: 03/12/2014] [Indexed: 01/05/2023]
Abstract
Biomaterials are essential to modern medicine as components of reconstructive implants, implantable sensors, and vehicles for localized drug delivery. Advances in biomaterials have led to progression from simply making implants that are nontoxic to making implants that are specifically designed to elicit particular functions within the host. The interaction of implants and the extracellular matrix during the foreign body response is a growing area of concern for the field of biomaterials, because it can lead to implant failure. Expression of matricellular proteins is modulated during the foreign body response and these proteins interact with biomaterials. The design of biomaterials to specifically alter the levels of matricellular proteins surrounding implants provides a new avenue for the design and fabrication of biomimetic biomaterials.
Collapse
Affiliation(s)
- Aaron H Morris
- Department of Biomedical Engineering, Yale University, New Haven, CT, United States
| | - Themis R Kyriakides
- Department of Biomedical Engineering, Yale University, New Haven, CT, United States; Department of Pathology, Yale University, New Haven, CT, United States; Vascular Biology and Therapeutics Program, Yale University, New Haven, CT, United States.
| |
Collapse
|
22
|
Fu Z, Yan K, Rosenberg A, Jin Z, Crain B, Athas G, Vander Heide RS, Howard T, Everett AD, Herrington D, Van Eyk JE. Improved protein extraction and protein identification from archival formalin-fixed paraffin-embedded human aortas. Proteomics Clin Appl 2013; 7:217-24. [PMID: 23339088 PMCID: PMC4340701 DOI: 10.1002/prca.201200064] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Revised: 11/07/2012] [Accepted: 12/10/2012] [Indexed: 01/04/2023]
Abstract
PURPOSE Evaluate combination of heat and elevated pressure to enhance protein extraction and quality of formalin-fixed (FF), and FF paraffin-embedded (FFPE) aorta for proteomics. EXPERIMENT DESIGN Proteins were extracted from fresh frozen aorta at room temperature (RT). FF and FFPE aortas (3 months and 15 years) were extracted at RT, heat alone, or a combination of heat and high pressure. Protein yields were compared, and digested peptides from the extracts were analyzed with MS. RESULTS Combined heat and elevated pressure increased protein yield from human FF or FFPE aorta compared to matched tissues with heat alone (1.5-fold) or at RT (8.3-fold), resulting in more proteins identified and with more sequence coverage. The length of storage did adversely affect the quality of proteins from FF tissue. For long-term storage, aorta was preserved better with FFPE than FF alone. Periostin and MGF-E8 were demonstrated suitable for MRM assays from FFPE aorta. CONCLUSIONS AND CLINICAL RELEVANCE Combination of heat and high pressure is an effective method to extract proteins from FFPE aorta for downstream proteomics. This method opens the possibility for use of archival and often rare FFPE aortas and possibly other tissues available to proteomics for biomarker discovery and quantification.
Collapse
Affiliation(s)
- Zongming Fu
- Johns Hopkins School of Medicine, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, 21224
| | - Kun Yan
- Johns Hopkins School of Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, 21224
| | - Avraham Rosenberg
- Johns Hopkins School of Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, 21224
| | - Zhicheng Jin
- Johns Hopkins School of Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, 21224
| | - Barbara Crain
- Johns Hopkins School of Medicine, Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21224
| | - Grace Athas
- Louisiana State University School of Medicine, New Orleans, LA, 70112
| | - Richard S Vander Heide
- Johns Hopkins School of Medicine, Department of Pathology, Johns Hopkins University, Baltimore, Maryland, 21224
| | - Timothy Howard
- Wake Forest University School of Medicine, Winston-Salem, NC 27157
| | - Allen D. Everett
- Johns Hopkins School of Medicine, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, 21224
| | - David Herrington
- Wake Forest University School of Medicine, Winston-Salem, NC 27157
| | - Jennifer E. Van Eyk
- Johns Hopkins School of Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, 21224
| |
Collapse
|
23
|
Irvin MR, Zhang Q, Kabagambe EK, Perry RT, Straka RJ, Tiwari HK, Borecki IB, Shimmin LC, Stuart C, Zhong Y, Hixson JE, Arnett DK. Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study. Pharmacogenet Genomics 2012; 22:367-72. [PMID: 22336959 PMCID: PMC3325369 DOI: 10.1097/fpc.0b013e328351a486] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
OBJECTIVE Fenofibrate, a peroxisome proliferator-activated receptor-α (PPARα) agonist, reduces triglyceride (TG) concentrations by 25-60%. Given significant interindividual variations in the TG response, we investigated the association of PPARA rare variants with treatment response in the Genetics of Lipid-Lowering Drugs and Diet Network study. METHODS We calculated the change in the TG concentration (ΔTG) among 861 GOLDN participants treated with fenofibrate (160 mg/day) for 3 weeks. From the distribution of ΔTG adjusted for age and sex, the 150 highest and 150 lowest fenofibrate responders were selected from the tails of the distribution for PPARA resequencing. The resequencing strategy was based on VariantSEQr technology for the amplification of exons and regulatory regions. RESULTS We identified 73 variants with an average minor allele frequency of 4.8% (range: 0.2-16%). We tested the association of rare variants located in a coding or a regulatory region (minor allele frequency<1%, 13 variants) with treatment response group by an indicator variable (presence/absence of ≥1 rare variant) using general linear mixed models to allow for adjustment for family relationship. After adjusting for baseline, fasting TG concentration carrying at least one rare variant was associated with a low fenofibrate response (odds ratio=6.46; 95% confidence interval: 1.4-30.8). Carrier status was also associated with a relative change in the total cholesterol concentration (P=0.02), but not high-density lipoprotein or low-density lipoprotein concentration. CONCLUSION Rare, potentially functional variants in PPARA may play a role in the TG response to fenofibrate, but future experimental studies will be necessary to replicate the findings and confirm functional effects.
Collapse
Affiliation(s)
- Marguerite R Irvin
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama 35294-0022, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|